{"ctNumber":"2024-518143-38-00","ctStatus":"Authorised","startDateEU":"2024-10-25","decisionDate":"2024-10-25T18:25:35.308","publishDate":"2026-04-15T03:48:01.33068466","ctPublicStatusCode":3,"authorizedApplication":{"authorizedPartI":{"id":101938,"rowSubjectCount":0,"products":[{"id":421874,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00230MIG","euMpNumber":"SCP129816","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"PACLITAXEL","euSubstNumber":"SUB09583MIG","productSubstances":[{"substancePk":"419891","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"PACLITAXEL","substanceEvCode":"SUB09583MIG","synonyms":["ONCOGEL","ABI-007","MBT 0206"]}],"atcCode":"L01CD01","atcName":"PACLITAXEL\r","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"125","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"4500","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","scientificProductEvCode":"SCP129816","scientificProductPharmEvCode":"PHF00230MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":true,"productName":"PACLITAXEL\r","jsonActiveSubstanceNames":"paclitaxel","pharmaceuticalFormDisplay":"PHF00230MIG"},{"id":421873,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11440371","productPharmForm":"CONCENTRATE FOR DISPERSION FOR INFUSION","euMpNumber":"PRD6811022","marketingAuthNumber":"EU/1/16/1130/001","prodAuthStatus":2,"prodName":"Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion","pharmForm":"CONCENTRATE FOR DISPERSION FOR INFUSION","activeSubstanceName":"IRINOTECAN","euSubstNumber":"SUB08295MIG","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/004125","nameOrg":"LES LABORATOIRES SERVIER (SURESNES)","productSubstances":[{"productPk":"11440371","substancePk":"352073","nameOrg":"LES LABORATOIRES SERVIER (SURESNES)","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"IRINOTECAN","substanceEvCode":"SUB08295MIG"}],"atcCode":"L01XX19","atcName":"IRINOTECAN","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"70","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"840","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","evCode":"PRD6811022","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":true,"productName":"Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion","jsonActiveSubstanceNames":"irinotecan","pharmaceuticalFormDisplay":"CONCENTRATE FOR DISPERSION FOR INFUSION"},{"id":421877,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB07892MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"GEMCITABINE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"GEMCITABINE","euSubstNumber":"SUB07892MIG","productSubstances":[{"substancePk":"28516","actSubstOrigin":"-","actSubstName":"GEMCITABINE","substanceEvCode":"SUB07892MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"1000","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"36000","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antimetabolite","scientificProductEvCode":"SUB07892MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"GEMCITABINE","jsonActiveSubstanceNames":"gemcitabine"},{"id":421875,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB13910MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FOLINIC ACID","pharmForm":"SOLUTION FOR INJECTION/INFUSION","activeSubstanceName":"FOLINIC ACID","euSubstNumber":"SUB13910MIG","productSubstances":[{"substancePk":"152102","actSubstOrigin":"Chemical","actSubstName":"FOLINIC ACID","substanceEvCode":"SUB13910MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"400","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"800","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"metabolite","scientificProductEvCode":"SUB13910MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"FOLINIC ACID","jsonActiveSubstanceNames":"folinic acid"},{"id":421876,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB07721MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLUOROURACIL","pharmForm":"CONCENTRATE FOR SOLUTION FOR INJECTION/INFUSION","activeSubstanceName":"FLUOROURACIL","euSubstNumber":"SUB07721MIG","productSubstances":[{"substancePk":"93381","actSubstOrigin":"Chemical","actSubstName":"FLUOROURACIL","substanceEvCode":"SUB07721MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"2400","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"4800","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","scientificProductEvCode":"SUB07721MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":false,"productName":"FLUOROURACIL","jsonActiveSubstanceNames":"fluorouracil"}],"trialDetails":{"clinicalTrialIdentifiers":{"fullTitle":"PRODIGE 61- FFCD 1702 - FUNGEMAX  Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer","fullTitleTranslations":[{"id":8119767,"uuid":"64a28632-43bf-4d06-a057-24b9345785ab","attributeTranslation":"PRODIGE 61- FFCD 1702 - FUNGEMAX Étude de Phase II randomisée pour les cancers du pancréas métastatiques comparant 5-FU/LV+Nal-IRI, versus gemcitabine+Nab-paclitaxel versus un schéma séquentiel alternant tous les 2 mois 5-FU/LV+Nal-IRI et gemcitabine+Nab-paclitaxel","language":34,"languageDescription":"French (France)"}],"publicTitle":"Randomized phase II study comparing 5FU/LV+Nal-IRI, gemcitabine+Nab-paclitaxel or a sequential regimen of 2 months 5FU/LV+Nal-IRI followed by two months of gemcitabine+Nab-paclitaxel, in metastatic pancreatic cancer","publicTitleTranslations":[{"id":8119783,"uuid":"d663ae14-96da-4a0a-9bac-d891c4b5bc16","attributeTranslation":"Étude de Phase II randomisée pour les cancers du pancréas métastatiques comparant 5-FU/LV+Nal-IRI, versus gemcitabine+Nab-paclitaxel versus un schéma séquentiel alternant tous les 2 mois 5-FU/LV+Nal-IRI et gemcitabine+Nab-paclitaxel","language":34,"languageDescription":"French (France)"}],"shortTitle":"FUNGEMAX","secondaryIdentifyingNumbers":{"nctNumber":{"id":437486,"number":"NCT03693677"},"additionalRegistries":[]}},"trialInformation":{"trialCategory":{"isLowIntervention":false,"trialPhase":"10","trialCategory":"2","justificationForTrialCategory":"Randomized phase II","trialCategoryId":92590},"medicalCondition":{"partIMedicalConditions":[{"id":105341,"medicalCondition":"Metastatic pancreatic cancer","medicalConditionTranslations":[{"id":8119739,"uuid":"a334a181-245a-4212-9734-c95c4e93eaf3","attributeTranslation":"Cancer du pancréas métastatique","language":34,"languageDescription":"French (France)"}],"isConditionRareDisease":false}]},"trialObjective":{"trialScopes":[{"code":"3","trialScopeId":305959}],"mainObjective":"-\tCompare the progression free survival at 6 months in experimental arms (arm A: Nal-Iri plus 5FU/LV and Nab-Paclitaxel plus Gemcitabine alternatively, arm B: Nal-Iri plus 5FU/LV) VS the reference arm (arm C: Nab-Paclitaxel plus Gemcitabine) according to the RECIST 1.1 criteria","mainObjectiveTranslations":[{"id":8119782,"uuid":"2b414e94-4560-4653-9fdd-f5e18a4ccb90","attributeTranslation":"-\tComparer la survie sans progression à 6 mois dans les bras expérimentaux (bras A : Nal-IRI + 5-FU/LV et Nab-Paclitaxel + Gemcitabine, alternativement ; bras B : Nal-IRI + 5-FU/LV) à celle du bras de référence (bras C : Nab-Paclitaxel + Gemcitabine) conformément aux critères RECIST 1.1 (selon l’investigateur).","language":34,"languageDescription":"French (France)"}],"secondaryObjectives":[{"id":352155,"number":1,"secondaryObjective":"-\tProgression free survival at 6 months (according to central review)","secondaryObjectiveTranslations":[{"id":8119784,"uuid":"d442fecc-c9ae-466b-9a2a-3dd7e43d2b84","attributeTranslation":"-\tSurvie sans progression 6 mois (selon la relecture centralisée)","language":34,"languageDescription":"French (France)"}]},{"id":352156,"number":2,"secondaryObjective":"-\tBest objective response rate","secondaryObjectiveTranslations":[{"id":8119785,"uuid":"55e8cb71-8dd9-479e-aa27-f4cc58d36a5f","attributeTranslation":"-\tMeilleure réponse objective","language":34,"languageDescription":"French (France)"}]},{"id":352157,"number":3,"secondaryObjective":"-\tDepth of response","secondaryObjectiveTranslations":[{"id":8119786,"uuid":"845bd38c-c5a7-43b3-ac9d-eebd465c6244","attributeTranslation":"-\tProfondeur de réponse","language":34,"languageDescription":"French (France)"}]},{"id":352158,"number":4,"secondaryObjective":"-\tEarly tumor shrinkage","secondaryObjectiveTranslations":[{"id":8119787,"uuid":"3614c370-08c1-47df-9486-1ddebb33d570","attributeTranslation":"-\tFonte tumorale précoce","language":34,"languageDescription":"French (France)"}]},{"id":352159,"number":5,"secondaryObjective":"-\tProgression free survival (according to the investigator and central review)","secondaryObjectiveTranslations":[{"id":8119788,"uuid":"40ac0af0-13c8-4815-9626-a3d7cde01cc1","attributeTranslation":"-\tSurvie sans progression (selon l’investigateur et selon la relecture centralisée)","language":34,"languageDescription":"French (France)"}]},{"id":352160,"number":6,"secondaryObjective":"-\tOverall survival","secondaryObjectiveTranslations":[{"id":8119789,"uuid":"6da4c1f8-2b84-41a5-ac18-4315fabd8875","attributeTranslation":"-\tSurvie globale","language":34,"languageDescription":"French (France)"}]},{"id":352161,"number":7,"secondaryObjective":"-\tTime to treatment failure","secondaryObjectiveTranslations":[{"id":8119790,"uuid":"845469c1-def2-41c8-8f4c-0e7b6ad74c6c","attributeTranslation":"-\tTemps jusqu’à échec thérapeutique","language":34,"languageDescription":"French (France)"}]},{"id":352162,"number":8,"secondaryObjective":"-\tSafety","secondaryObjectiveTranslations":[{"id":8119791,"uuid":"fb1d4a17-ac87-4ab1-8ade-771094f85c09","attributeTranslation":"-\tTolérance","language":34,"languageDescription":"French (France)"}]},{"id":352163,"number":9,"secondaryObjective":"-\tQuality of life (EORTC QLQ-C30)","secondaryObjectiveTranslations":[{"id":8119792,"uuid":"1a6492d7-316f-465a-ac27-d4a0f20aad46","attributeTranslation":"-\tQualité de vie (Questionnaire EORTC QLQ-C30)","language":34,"languageDescription":"French (France)"}]},{"id":352164,"number":10,"secondaryObjective":"-\tCA 19-9 and CEA monitoring","secondaryObjectiveTranslations":[{"id":8119793,"uuid":"db32bf07-a462-4130-a23d-40c22e2ef610","attributeTranslation":"-\tSurveillance des marqueurs CA 19-9 et de l’ACE","language":34,"languageDescription":"French (France)"}]}]},"eligibilityCriteria":{"principalInclusionCriteria":[{"id":676760,"number":1,"principalInclusionCriteria":"-\tHistopathologically or cytologically proven pancreatic adenocarcinoma (on primitive or metastatic lesion)","principalInclusionCriteriaTranslations":[{"id":8119768,"uuid":"71e82567-096b-4583-ac32-02a63ecd1bf9","attributeTranslation":"-\tAdénocarcinome pancréatique histologiquement ou cytologiquement prouvé (sur lésion primitive ou métastatique)","language":34,"languageDescription":"French (France)"}]},{"id":676761,"number":10,"principalInclusionCriteria":"-\tNormal ECG or ECG without any clinically significant findings","principalInclusionCriteriaTranslations":[{"id":8119769,"uuid":"b51b8a0c-888d-4128-9f7b-fbbeff92b820","attributeTranslation":"-\tECG normal ou ECG sans résultats cliniquement significatifs","language":34,"languageDescription":"French (France)"}]},{"id":676762,"number":11,"principalInclusionCriteria":"-\tPatient able to understand and sign an informed consent","principalInclusionCriteriaTranslations":[{"id":8119770,"uuid":"61dcdb51-eed3-47fa-899a-0c73204b0c32","attributeTranslation":"-\tPatient capable de comprendre et de signer un consentement éclairé","language":34,"languageDescription":"French (France)"}]},{"id":676763,"number":12,"principalInclusionCriteria":"-\tFemales of child-bearing potential are required to test negative for pregnancy at the time of enrollment based on a urine or serum pregnancy test.","principalInclusionCriteriaTranslations":[{"id":8119771,"uuid":"16031812-9411-44e2-847b-99299c6c6be4","attributeTranslation":"-\tLes femmes en âge de procréer doivent avoir un test de grossesse sérique ou urinaire négatif au moment de l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":676764,"number":13,"principalInclusionCriteria":"-\tBoth male and female patients of reproductive potential were required to agree to use a reliable method of birth control, during the study and for 7 months following the last dose of study drug.","principalInclusionCriteriaTranslations":[{"id":8119772,"uuid":"0a43498a-3897-4dae-810b-fbf401c314a3","attributeTranslation":"-\tLes femmes en âge de procréer ainsi que les hommes (ayant des rapports sexuels avec des femmes en âge de procréer) doivent s’engager à utiliser des moyens de contraception efficaces tout au long de l’étude et au cours des 7 mois suivant l’administration de la dernière dose du médicament à l’étude.","language":34,"languageDescription":"French (France)"}]},{"id":676765,"number":14,"principalInclusionCriteria":"-\tPatient affiliated to social security -\tRegular follow-up possible","principalInclusionCriteriaTranslations":[{"id":8119773,"uuid":"63aba6a3-7b25-4516-b3ca-9763249acaf5","attributeTranslation":"-\tPatient affilié à la Sécurité sociale.\n-\tSuivi régulier possible","language":34,"languageDescription":"French (France)"}]},{"id":676766,"number":2,"principalInclusionCriteria":"-\tMetastatic disease at a distance","principalInclusionCriteriaTranslations":[{"id":8119774,"uuid":"38f542bd-95e4-4346-bd3e-64a2d16dd9d5","attributeTranslation":"-\tMaladie métastatique à distance","language":34,"languageDescription":"French (France)"}]},{"id":676767,"number":3,"principalInclusionCriteria":"-\tAt least one measurable lesion according RECIST v1.1 criteria","principalInclusionCriteriaTranslations":[{"id":8119775,"uuid":"0659f4f9-398b-4432-bcd5-00009dc0d1cc","attributeTranslation":"-\tAu moins une lésion mesurable selon les critères RECIST v1.1","language":34,"languageDescription":"French (France)"}]},{"id":676768,"number":4,"principalInclusionCriteria":"-\t18 ≤ age ≤ 75 years  -\tLife expectancy >12 weeks -\tPerformance status WHO < 2","principalInclusionCriteriaTranslations":[{"id":8119776,"uuid":"f83bd95e-99b6-4800-98ea-ee92eb89c5ef","attributeTranslation":"-\tÂge : ≥ 18 ans et ≤ 75 ans \n-\tEspérance de vie > 12 semaines\n-\tIndice de performance (OMS) < 2","language":34,"languageDescription":"French (France)"}]},{"id":676769,"number":5,"principalInclusionCriteria":"-\tNo prior chemotherapy: adjuvant chemotherapy by gemcitabine +/- capecitabine is allowed if ended at least 12 months before the inclusion and adjuvant or neo-adjuvant FOLRIFINOX chemotherapy is allowed if ended at least 12 months prior the inclusion","principalInclusionCriteriaTranslations":[{"id":8119777,"uuid":"cb944bea-9553-4f21-af17-c552f0cd2a8e","attributeTranslation":"gemcitabine +/- capécitabine est autorisée si elle a pris fin au moins 12 mois avant l’inclusion et la chimiothérapie néo-adjuvante ou adjuvante avec FOLFIRINOX est autorisée si elle a pris fin au moins 12 mois avant l’inclusion","language":34,"languageDescription":"French (France)"}]},{"id":676770,"number":6,"principalInclusionCriteria":"-\tPain well controlled before the inclusion of the patient","principalInclusionCriteriaTranslations":[{"id":8119778,"uuid":"c840cc4b-c220-4624-998b-a82fe6a5afb4","attributeTranslation":"-\tDouleur bien contrôlée avant l’inclusion du patient","language":34,"languageDescription":"French (France)"}]},{"id":676771,"number":7,"principalInclusionCriteria":"-\tANC ≥ 1,500 cells/μL (without the use of hematopoietic growth factors); platelet count ≥ 100,000 cells/μL, hemoglobin ≥ 9 g/dL (blood transfusions is permitted for patients with hemoglobin levels below 9 g/dL)","principalInclusionCriteriaTranslations":[{"id":8119779,"uuid":"fe822670-df55-4082-a2f1-bc9715118121","attributeTranslation":"-\tPNN ≥ 1 500/mm3 (sans utiliser de facteurs de croissance hématopoïétiques) ; Plaquettes ≥ 100 000/mm3 ; hémoglobine ≥ 9 g/dl (les transfusions sont permises pour les patients présentant un taux d’hémoglobine inférieur à 9 g/dl)","language":34,"languageDescription":"French (France)"}]},{"id":676772,"number":8,"principalInclusionCriteria":"-\tAdequate hepatic function as evidenced by: Serum total bilirubin within normal range for the institution (Serum bilirubin ≤ 1,5 UNL) Biliary drainage allowed for biliary obstruction.","principalInclusionCriteriaTranslations":[{"id":8119780,"uuid":"524de3e5-d5ad-434f-95e2-29fa43eed2ad","attributeTranslation":"-\tFonction hépatique satisfaisante : ASAT et ALAT ≤ 2,5 x LSN (≤ 5 x LSN si des métastases hépatiques) ; bilirubine totale sérique ≤ 1,5 x LSN. Drainage biliaire autorisé en cas d’obstruction biliaire","language":34,"languageDescription":"French (France)"}]},{"id":676773,"number":9,"principalInclusionCriteria":"-\tAlbumin levels ≥ 3.0 g/dL -\tAspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 x ULN (≤ 5 x ULN acceptable if liver metastases were present) -\tNormal renal function test (creatinine clearance ≥ 50 ml/min)","principalInclusionCriteriaTranslations":[{"id":8119781,"uuid":"edd6f401-2192-4a54-aaa9-e07e997fa6f7","attributeTranslation":"-\tFonction hépatique satisfaisante : ASAT et ALAT ≤ 2,5 x LSN (≤ 5 x LSN si des métastases hépatiques) ; \nbilirubine totale sérique ≤ 1,5 x LSN. Drainage biliaire autorisé en cas d’obstruction biliaire Taux d’albumine ≥ 3,0 g/dl\n-\tFonction rénale normale (clairance MDRD de la créatinine ≥ 50 ml/min)","language":34,"languageDescription":"French (France)"}]}],"principalExclusionCriteria":[{"id":1163251,"number":1,"principalExclusionCriteria":"-\tUncontrolled brain or meningeal metastasis, or bone metastasis (no need of systematic CT scan)","principalExclusionCriteriaTranslations":[{"id":8119750,"uuid":"8423dc65-1d9c-4828-af00-626b04b76533","attributeTranslation":"-\tMétastases cérébrales non contrôlées, métastases méningées ou osseuses connues (TDM systématique inutile)","language":34,"languageDescription":"French (France)"}]},{"id":1163252,"number":10,"principalExclusionCriteria":"-\tNYHA Class III or IV congestive heart failure, ventricular arrhythmias or uncontrolled blood pressure.","principalExclusionCriteriaTranslations":[{"id":8119751,"uuid":"61d8e6f7-db14-4308-893e-c37071b0be7f","attributeTranslation":"-\tInsuffisance cardiaque congestive de Classe III ou IV selon la classification du NYHA, arythmie ventriculaire ou tension artérielle non contrôlée","language":34,"languageDescription":"French (France)"}]},{"id":1163253,"number":11,"principalExclusionCriteria":"-\tKnown hypersensitivity to any of the drugs /constituents or non-lipososomal irinotecan","principalExclusionCriteriaTranslations":[{"id":8119752,"uuid":"95f114c8-921d-49cd-a0ac-bc91759fb2d3","attributeTranslation":"-\tTout autre problème médical ou social qui, selon l’investigateur, pourrait être susceptible d’entraver la capacité du patient à signer le consentement éclairé, coopérer et participer à l’étude, interférer dans l’interprétation des résultats","language":34,"languageDescription":"French (France)"}]},{"id":1163254,"number":12,"principalExclusionCriteria":"-\tAny other medical or social condition deemed by the investigator to be likely to interfere with a patient’s ability to sign informed consent, cooperate and participate in the study, or interferes with the interpretation of the results","principalExclusionCriteriaTranslations":[{"id":8119753,"uuid":"b1903d1c-57d3-4285-83c7-714ad9d2ac34","attributeTranslation":"-\tHypersensibilité connue à l’un des médicaments / composants du traitement, ou à l’irinotécan non liposomal.","language":34,"languageDescription":"French (France)"}]},{"id":1163255,"number":13,"principalExclusionCriteria":"-\tUse of CYP3A4/UGT1A inducers/inhibitors","principalExclusionCriteriaTranslations":[{"id":8119754,"uuid":"2ac20c80-4320-4588-8733-3805f119ff65","attributeTranslation":"-\tUtilisation d’inducteurs / inhibiteurs du CYP3A4 / UGT1A1","language":34,"languageDescription":"French (France)"}]},{"id":1163256,"number":14,"principalExclusionCriteria":"-\tUse of strong CYP2C8 inhibitors or inducers, or presence of any other contraindications for nab-paclitaxel or gemcitabine","principalExclusionCriteriaTranslations":[{"id":8119755,"uuid":"4ddeb62c-243a-4ab0-a570-9a77446f4924","attributeTranslation":"-\tUtilisation d’inhibiteurs ou d’inducteurs puissants du CYP2C8, ou présence de toute autre contre-indication à l’administration de Nab-paclitaxel ou de gemcitabine","language":34,"languageDescription":"French (France)"}]},{"id":1163257,"number":15,"principalExclusionCriteria":"-\tILD presence","principalExclusionCriteriaTranslations":[{"id":8119756,"uuid":"20abeb73-0e2b-4aad-a38a-38f6604a6cae","attributeTranslation":"-\tPrésence d’une pneumopathie interstitielle","language":34,"languageDescription":"French (France)"}]},{"id":1163258,"number":16,"principalExclusionCriteria":"-\tPartial or complete DPD deficiency (Uracilemia ≥ 16 ng/ml)","principalExclusionCriteriaTranslations":[{"id":8119757,"uuid":"61ec38ce-c6fe-4494-b6c4-3ba74defe1ae","attributeTranslation":"-\tDéficit complet ou partiel en DPD (Uracilémie ≥ 16 ng/ml)","language":34,"languageDescription":"French (France)"}]},{"id":1163259,"number":17,"principalExclusionCriteria":"-\tPregnant or breast feeding","principalExclusionCriteriaTranslations":[{"id":8119758,"uuid":"c6414283-cf0a-46e7-a3f1-7a9f74dd49b0","attributeTranslation":"-\tLes femmes enceintes ou en phase d’allaitement.","language":34,"languageDescription":"French (France)"}]},{"id":1163260,"number":2,"principalExclusionCriteria":"-\tPrior radiation therapy (except if there is at least one measurable target outside irradiation area)","principalExclusionCriteriaTranslations":[{"id":8119759,"uuid":"96162724-80f5-4fcb-8663-aa49ae23b6b4","attributeTranslation":"-\tRadiothérapie antérieure (sauf s’il persiste au moins une cible mesurable en dehors de la zone irradiée)","language":34,"languageDescription":"French (France)"}]},{"id":1163261,"number":3,"principalExclusionCriteria":"-\tClinically significant gastrointestinal disorder including hepatic disorders, bleeding, inflammation, occlusion, or diarrhea > Grade 1","principalExclusionCriteriaTranslations":[{"id":8119760,"uuid":"e3d87b22-739b-4bb0-99ff-5d752ee08ac0","attributeTranslation":"-\tTrouble gastro-intestinal cliniquement significatif, y compris les troubles hépatiques, les saignements, l'inflammation, l'occlusion ou la diarrhée > Grade 1","language":34,"languageDescription":"French (France)"}]},{"id":1163262,"number":4,"principalExclusionCriteria":"-\tHistory of chronic inflammatory bowel disease","principalExclusionCriteriaTranslations":[{"id":8119761,"uuid":"5a2bfec1-a0c1-4110-bcd2-b2495c9db823","attributeTranslation":"-\tAntécédents de maladies inflammatoires chronique de l’intestin (MICI)","language":34,"languageDescription":"French (France)"}]},{"id":1163263,"number":5,"principalExclusionCriteria":"-\tOther types of pancreatic tumours, in particular endocrine or acinar cell tumours","principalExclusionCriteriaTranslations":[{"id":8119762,"uuid":"34dfc282-a59e-4392-ae38-f00a0cb5ea05","attributeTranslation":"-\tAutres types de tumeurs pancréatiques, en particulier tumeurs endocrines ou à cellules acineuses","language":34,"languageDescription":"French (France)"}]},{"id":1163264,"number":6,"principalExclusionCriteria":"-\tAmpulloma -\tGilbert's syndrome","principalExclusionCriteriaTranslations":[{"id":8119763,"uuid":"edc8f9c5-a2b6-4bce-90bf-7d477a23f180","attributeTranslation":"-\tAmpullome\n-\tMaladie de Gilbert","language":34,"languageDescription":"French (France)"}]},{"id":1163265,"number":7,"principalExclusionCriteria":"-\tPresence of neuropathy > grade 1 according to NCI-CTC","principalExclusionCriteriaTranslations":[{"id":8119764,"uuid":"691829db-e43a-4d68-acc6-f7b9e7163419","attributeTranslation":"-\tPrésence de neuropathie > grade 1 selon le NCI-CTC","language":34,"languageDescription":"French (France)"}]},{"id":1163266,"number":8,"principalExclusionCriteria":"-\tHistory of any second malignancy in the last 5 years; subjects with prior history of in-situ cancer or basal or squamous cell skin cancer are eligible. Subjects with other malignancies are eligible if they had been continuously disease free for at least 5 years.","principalExclusionCriteriaTranslations":[{"id":8119765,"uuid":"e9458e94-260d-4281-b03b-3b2a761134d6","attributeTranslation":"-\tAntécédents de cancer au cours des 5 dernières années ; les patients présentant des antécédents de cancer in-situ ou de carcinome basocellulaire ou épidermoïde, considéré comme guéri, sont éligibles.","language":34,"languageDescription":"French (France)"}]},{"id":1163267,"number":9,"principalExclusionCriteria":"-\tSevere arterial thromboembolic events (myocardial infarction, unstable angina pectoris, stroke) less than 6 months before inclusion.","principalExclusionCriteriaTranslations":[{"id":8119766,"uuid":"0803f81b-6f24-4118-9b9b-67e53714d2ee","attributeTranslation":"-\tÉvénements de type thromboembolique artérielle grave (infarctus du myocarde, angor instable, AVC) datant de moins de 6 mois avant l’inclusion.","language":34,"languageDescription":"French (France)"}]}]},"endPoint":{"primaryEndPoints":[{"id":792390,"number":1,"endPoint":"The primary endpoint is the rate of patients alive without progression at 6 months after inclusion","isPrimary":true,"endPointTranslations":[{"id":8119740,"uuid":"5be999c8-fd2f-4c1f-bf82-148d767eb444","attributeTranslation":"Le critère principal est le taux de patients vivants, sans progression, 6 mois après la randomisation.","language":34,"languageDescription":"French (France)"}]}],"secondaryEndPoints":[{"id":792391,"number":1,"endPoint":"Best Objective Response (BOR): BOR is defined as complete or partial response rate according to scans and RECIST v1.1 criteria over the entire treatment period.","isPrimary":false,"endPointTranslations":[{"id":8119741,"uuid":"2baf731f-9a6d-4963-b1ef-fec24083eae0","attributeTranslation":"Meilleure réponse objective : Elle est définie comme étant le taux de réponses complètes ou partielles obtenu à partir des imageries, selon les critères RECIST v1.1, sur l’ensemble du traitement.","language":34,"languageDescription":"French (France)"}]},{"id":792392,"number":2,"endPoint":"Progression free survival (PFS): PFS is defined as the time between the date of randomization and the date of the first radiological and/or clinical progression or the date of death (for whatever reason).","isPrimary":false,"endPointTranslations":[{"id":8119742,"uuid":"26485bb2-b11b-4387-b65f-19e637401451","attributeTranslation":"Survie sans progression (SSP) : Elle est définie comme le délai entre la date de randomisation et la date de la première progression radiologique et/ou clinique ou la date du décès (toutes causes confondues).","language":34,"languageDescription":"French (France)"}]},{"id":792393,"number":3,"endPoint":"Overall survival (OS): OS is defined as the time between the date of randomization and the date of death (whatever the cause).","isPrimary":false,"endPointTranslations":[{"id":8119743,"uuid":"275d1d69-3957-4707-a668-7a7c8b0a566f","attributeTranslation":"Survie globale (SG) : Elle est définie comme le délai entre la date de randomisation et la date du décès (toutes causes confondues).","language":34,"languageDescription":"French (France)"}]},{"id":792394,"number":4,"endPoint":"Depth of response: This is defined as the relative difference between the sum of the largest diameters of target lesions in the NADIR (in the absence of new lesions or progression of non-target lesions) and the sum of the largest diameters of the target lesions at inclusion.","isPrimary":false,"endPointTranslations":[{"id":8119744,"uuid":"8943ffc1-cf2b-4832-b060-5abc4305f2a4","attributeTranslation":"Profondeur de réponse : Elle est définie comme la différence relative entre la somme des plus grands diamètres des lésions cibles au NADIR (en l'absence d’apparition de nouvelles lésions ou de progression des lésions non cibles) et la somme des plus grands diamètres des lésions cibles à l'inclusion.","language":34,"languageDescription":"French (France)"}]},{"id":792395,"number":5,"endPoint":"Early tumor shrinkage: This is defined as the relative difference between the sum of the largest diameters of target lesions at 8 weeks and this sum at inclusion. Early decrease corresponds to a relative difference of > 20% in RECIST v1.1.","isPrimary":false,"endPointTranslations":[{"id":8119745,"uuid":"637f5ffb-1a5f-4b08-a8db-af74614735fe","attributeTranslation":"Fonte tumorale précoce : Elle est définie comme la différence relative entre la somme des plus grands diamètres des lésions cibles à 8 semaines et la somme des mêmes cibles à l'inclusion. Une fonte tumorale correspond à une différence relative > 20 % en RECIST v1.1.","language":34,"languageDescription":"French (France)"}]},{"id":792396,"number":6,"endPoint":"Time to treatment failure is defined as the time between the date of randomization and the date of discontinuation of all protocol treatments (regardless of cause) or date last news for patients alive under treatment.","isPrimary":false,"endPointTranslations":[{"id":8119746,"uuid":"d6b45df7-faaf-4cd5-a385-a2a7f8441b11","attributeTranslation":"Le temps jusqu’à échec thérapeutique est défini comme le délai entre la date de randomisation et la date d’arrêt de l’ensemble des traitements liés au protocole (quel que soit la cause) ou la date de dernières nouvelles pour les patients vivants et sous traitement.","language":34,"languageDescription":"French (France)"}]},{"id":792397,"number":7,"endPoint":"Safety: Toxicities are evaluated according to NCI-CTC v4.0.","isPrimary":false,"endPointTranslations":[{"id":8119747,"uuid":"27a4f7e5-d6a4-4938-9983-477d7f835b71","attributeTranslation":"Tolérance : Les toxicités sont évaluées selon le NCI-CTC v4.0.","language":34,"languageDescription":"French (France)"}]},{"id":792398,"number":8,"endPoint":"Quality of life (EORTC QLQ-C30): Quality of life will be assessed according to the questionnaire of EORTC QLQ-C30","isPrimary":false,"endPointTranslations":[{"id":8119748,"uuid":"dd3f1901-d349-4049-bc6f-cb25ce96aab1","attributeTranslation":"Qualité de vie (Questionnaire EORTC QLQ-C30) : La qualité de vie sera évaluée conformément au questionnaire EORTC QLQ-C30.","language":34,"languageDescription":"French (France)"}]},{"id":792399,"number":9,"endPoint":"Evolution of tumoral markers: The evolution of the markers will be analysed by a graphical representation at each time points of the percentage change from baseline.","isPrimary":false,"endPointTranslations":[{"id":8119749,"uuid":"ce1a85df-50ed-4ec5-a2c0-4cf05ce908b9","attributeTranslation":"Évolution des marqueurs tumoraux : L’évolution des marqueurs sera analysée par une représentation graphique à chaque suivi du pourcentage d’évolution depuis l’inclusion.","language":34,"languageDescription":"French (France)"}]}]},"trialDuration":{"estimatedEndDate":"2026-12-30","estimatedRecruitmentStartDate":"2018-11-16"},"sourceOfMonetarySupport":[],"populationOfTrialSubjects":{"ageRanges":[{"id":279398,"ageRangeCategoryCode":"3","ageRangeCategory":"3"},{"id":279397,"ageRangeCategoryCode":"4","ageRangeCategory":"4"}],"ageRangeSecondaryIds":[],"clinicalTrialGroups":[{"code":"2","name":"Patients"}],"isFemaleSubjects":true,"isMaleSubjects":true,"isVulnerablePopulationSelected":false},"individualParticipantData":{"planToShareIPD":"2"}},"protocolInformation":{"studyDesign":{"periodDetails":[]}},"scientificAdviceAndPip":{"scientificAdvices":[],"paediatricInvestigationPlan":[]},"associatedClinicalTrials":[],"references":[],"pubmedCode":[],"pubmedUrl":[]},"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-15","conclusionDate":"2025-10-15","therapeuticAreas":[{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}],"medicalConditions":[{"id":105341,"medicalCondition":"Metastatic pancreatic cancer","isConditionRareDisease":false}],"sponsors":[{"id":114369,"primary":true,"publicContacts":[{"id":337319,"type":"Public","functionalName":"JULIEN TAIEB","functionalEmailAddress":"julien.taieb@aphp.fr","telephone":"+33156093551","organisation":{"id":627460,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondation Franc.Cancerologie Digestive","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007358","organisationLocationStatus":"Active"}}],"scientificContacts":[{"id":337320,"type":"Scientific","functionalName":"JULIEN TAIEB","functionalEmailAddress":"julien.taieb@aphp.fr","telephone":"+33156093551","organisation":{"id":627460,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondation Franc.Cancerologie Digestive","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007358","organisationLocationStatus":"Active"}}],"thirdParties":[],"organisation":{"id":627460,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondation Franc.Cancerologie Digestive","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007358","organisationLocationStatus":"Active"},"addresses":[{"id":594653,"organisation":{"id":627460,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Fondation Franc.Cancerologie Digestive","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100007358","organisationLocationStatus":"Active"},"address":{"addressId":641745,"oneLine":"7 Boulevard Jeanne D Arc","addressLine1":"7 Boulevard Jeanne D Arc","addressLine2":"","addressLine3":"","addressLine4":"","city":"Dijon Cedex","postcode":"21001","country":2012,"countryName":"France"},"isBusinessKeyValidated":true,"businessKey":"ORG-100007358"}],"isCommercial":false,"commercial":"Non-Commercial"}],"trialCategoryCode":"2","trialCategoryJustificationComment":"Randomized phase II","partOneTherapeuticAreas":[{"id":976532,"therapeuticArea":{"code":"4","name":"Diseases [C] - Neoplasms [C04]"}}],"productRoleGroupInfos":[{"id":317420,"comments":"PACLITAXEL\r","productRoleCode":"1","productRoleName":"Test","products":[{"id":421874,"part1MpRoleTypeCode":"2","productDictionaryInfo":{"productPharmForm":"PHF00230MIG","euMpNumber":"SCP129816","marketingAuthNumber":"-","prodAuthStatus":2,"activeSubstanceName":"PACLITAXEL","euSubstNumber":"SUB09583MIG","productSubstances":[{"substancePk":"419891","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"PACLITAXEL","substanceEvCode":"SUB09583MIG","synonyms":["ONCOGEL","ABI-007","MBT 0206"]}],"atcCode":"L01CD01","atcName":"PACLITAXEL\r","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"125","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"4500","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","scientificProductEvCode":"SCP129816","scientificProductPharmEvCode":"PHF00230MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENIOUS INFUSION"],"allSubstancesChemicals":true,"productName":"PACLITAXEL\r","jsonActiveSubstanceNames":"paclitaxel","pharmaceuticalFormDisplay":"PHF00230MIG"}]},{"id":317421,"comments":"FOLINIC ACID","productRoleCode":"1","productRoleName":"Test","products":[{"id":421875,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB13910MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FOLINIC ACID","pharmForm":"SOLUTION FOR INJECTION/INFUSION","activeSubstanceName":"FOLINIC ACID","euSubstNumber":"SUB13910MIG","productSubstances":[{"substancePk":"152102","actSubstOrigin":"Chemical","actSubstName":"FOLINIC ACID","substanceEvCode":"SUB13910MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"400","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"800","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"metabolite","scientificProductEvCode":"SUB13910MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"FOLINIC ACID","jsonActiveSubstanceNames":"folinic acid"}]},{"id":317422,"comments":"FLUOROURACIL","productRoleCode":"1","productRoleName":"Test","products":[{"id":421876,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB07721MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"FLUOROURACIL","pharmForm":"CONCENTRATE FOR SOLUTION FOR INJECTION/INFUSION","activeSubstanceName":"FLUOROURACIL","euSubstNumber":"SUB07721MIG","productSubstances":[{"substancePk":"93381","actSubstOrigin":"Chemical","actSubstName":"FLUOROURACIL","substanceEvCode":"SUB07721MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"2400","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"4800","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","scientificProductEvCode":"SUB07721MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS ADMINISTRATION"],"allSubstancesChemicals":false,"productName":"FLUOROURACIL","jsonActiveSubstanceNames":"fluorouracil"}]},{"id":317423,"comments":"GEMCITABINE","productRoleCode":"1","productRoleName":"Test","products":[{"id":421877,"part1MpRoleTypeCode":"3","productDictionaryInfo":{"euMpNumber":"SUB07892MIG","marketingAuthNumber":"-","prodAuthStatus":2,"prodName":"GEMCITABINE","pharmForm":"POWDER FOR SOLUTION FOR INFUSION","activeSubstanceName":"GEMCITABINE","euSubstNumber":"SUB07892MIG","productSubstances":[{"substancePk":"28516","actSubstOrigin":"-","actSubstName":"GEMCITABINE","substanceEvCode":"SUB07892MIG"}],"atcCode":"-","atcName":"-","atcTermLevel":"-","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"1000","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"36000","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antimetabolite","scientificProductEvCode":"SUB07892MIG","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":false,"productName":"GEMCITABINE","jsonActiveSubstanceNames":"gemcitabine"}]},{"id":317419,"comments":"Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion","productRoleCode":"1","productRoleName":"Test","products":[{"id":421873,"part1MpRoleTypeCode":"1","productDictionaryInfo":{"productPk":"11440371","productPharmForm":"CONCENTRATE FOR DISPERSION FOR INFUSION","euMpNumber":"PRD6811022","marketingAuthNumber":"EU/1/16/1130/001","prodAuthStatus":2,"prodName":"Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion","pharmForm":"CONCENTRATE FOR DISPERSION FOR INFUSION","activeSubstanceName":"IRINOTECAN","euSubstNumber":"SUB08295MIG","authorisationCountryCode":"EU","mrpNumber":"EMEA/H/C/004125","nameOrg":"LES LABORATOIRES SERVIER (SURESNES)","productSubstances":[{"productPk":"11440371","substancePk":"352073","nameOrg":"LES LABORATOIRES SERVIER (SURESNES)","substanceOrigin":"Chemical","actSubstOrigin":"Chemical","actSubstName":"IRINOTECAN","substanceEvCode":"SUB08295MIG"}],"atcCode":"L01XX19","atcName":"IRINOTECAN","atcTermLevel":"5","activeSubstanceOtherDescriptiveName":""},"isPaediatricFormulation":false,"mpRoleInTrial":"1","orphanDrugEdit":false,"doseUom":"mg/m2 milligram(s)/sq. meter","maxDailyDoseAmount":"70","doseUomTotal":"mg/m2 milligram(s)/sq. meter","maxTotalDoseAmount":"840","productChangedRelationMA":false,"maxTreatmentPeriod":12,"timeUnitCode":"3","otherMedicinalProduct":"antineoplasic","evCode":"PRD6811022","devices":[],"characteristics":["11"],"routes":["INTRAVENOUS INFUSION"],"allSubstancesChemicals":true,"productName":"Onivyde pegylated liposomal 4.3 mg/ml concentrate for dispersion for infusion","jsonActiveSubstanceNames":"irinotecan","pharmaceuticalFormDisplay":"CONCENTRATE FOR DISPERSION FOR INFUSION"}]}],"isLowIntervention":false},"authorizedPartsII":[{"id":244885,"mscId":40409,"mscInfo":{"id":40409,"clinicalTrialId":19288,"countryOrganisationId":2012,"reportingStatusCode":"Authorised","fromDate":"2024-10-15","toDate":"2024-10-15","isProposedRms":true,"countryName":"France","organisationInfo":{},"firstDecisionDate":"2024-10-25","trialStatus":"Authorised","trialPeriod":[{"id":79604,"trialStartDate":"2024-10-25","fromDate":"2026-04-14"},{"id":79605,"trialStartDate":"2024-10-25","fromDate":"2026-04-14"}],"trialRecruitmentPeriod":[],"hasRecruitmentStarted":false,"activeTrialPeriod":{"id":128905,"trialStartDate":"2024-10-25","fromDate":"2026-04-14"},"activeTrialRecruitmentPeriod":{},"isWillingAtDayThreeView":false,"clinicalTrialStatusHistory":[{"id":54832,"mscId":40409,"trialStatus":"Under evaluation","trialStatusDate":"2024-10-02T09:38:53.571"},{"id":58842,"mscId":40409,"trialStatus":"Authorised","trialStatusDate":"2024-10-25T18:25:34.992"}],"applicationTypeMsc":"1","mscName":"France","assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-09","decision":"authorized","decisionDate":"2024-10-25"},"decisionDate":"2024-10-25","recruitmentSubjectCount":288,"trialSites":[{"id":1664996,"organisationAddressInfo":{"id":833134,"organisation":{"id":874265,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier De La Cote Basque","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100041218","organisationLocationStatus":"Active"},"address":{"addressId":925355,"oneLine":"13 Avenue Interne Jacques Loeb","addressLine1":"13 Avenue Interne Jacques Loeb","addressLine2":"","addressLine3":"","addressLine4":"","city":"Bayonne","postcode":"64100","country":2012,"countryName":"France"},"phone":"+33559443722","email":"faudemar@ch-cotebasque.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100041218"},"personInfo":{"id":1850879,"firstName":"Franck","lastName":"AUDEMAR","telephone":"+33559443722","email":"faudemar@ch-cotebasque.fr","title":"1"},"departmentName":"Hepato gastro enterology"},{"id":1664995,"organisationAddressInfo":{"id":826298,"organisation":{"id":865713,"type":"Hospital/Clinic/Other health care facility","typeCode":"8","name":"Centre Hospitalier Et Universitaire De Limoges","commercial":false,"isBusinessKeyValidated":true,"businessKey":"ORG-100009390","organisationLocationStatus":"Active"},"address":{"addressId":916844,"oneLine":"2 Avenue Martin Luther King","addressLine1":"2 Avenue Martin Luther King","addressLine2":"","addressLine3":"","addressLine4":"","city":"Limoges","postcode":"87000","country":2012,"countryName":"France"},"phone":"+33555056396","email":"frederic.thuillier@chu-limoges.fr","isBusinessKeyValidated":true,"businessKey":"ORG-100009390"},"personInfo":{"id":1850878,"firstName":"Frédéric","lastName":"THUILLIER","telephone":"+33555056396","email":"frederic.thuillier@chu-limoges.fr","title":"1"},"departmentName":"Digestive oncology"},{"id":1664994,"organisationAddressInfo":{"id":426816,"organisation":{"id":458717,"type":"Health care","typeCode":"2","name":"Hopital Europeen Georges Pompidou","commercial":false,"isBusinessKeyValidated":false,"businessKey":"ORL-000007250","organisationLocationStatus":"Active"},"address":{"addressId":456703,"oneLine":"20 Rue Leblanc","addressLine1":"20 Rue Leblanc","addressLine2":"","addressLine3":"","addressLine4":"","city":"Paris","postcode":"75015","country":2012,"countryName":"France"},"phone":"+33156093461","email":"Jean.pastre@aphp.fr","isBusinessKeyValidated":false,"businessKey":"ORL-000007250"},"personInfo":{"id":1850877,"firstName":"Julien","lastName":"TAIEB","telephone":"+33156093551","email":"julien.taieb@aphp.fr","title":"2"},"departmentName":"Hepato gastro enterology"}],"applicationStatusCode":"Authorised"}],"applicationInfo":[{"id":35813,"type":"INITIAL","status":"Authorised","ctNumber":"2024-518143-38-00","trialStatus":"Authorised","submissionDate":"2024-10-02","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-18"},"partIIInfo":[{"id":147523,"mscId":40409,"mscInfo":{"id":40409,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2024-10-21","decision":"authorized","decisionDate":"2024-10-25","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-10-25"},"applicationStatusCode":"Authorised"}],"decisionDate":"2024-10-25","ctMSCsByApplication":[{"id":40409,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"IN","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":43648,"applicationId":35813,"mscId":40409,"mscName":"France","decisionDate":"2024-10-25T18:25:35.308","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":147523,"part1Id":59071,"applicationType":"INITIAL","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"22e96967-2438-4793-8d52-fbaf107977cf","productRoleGroupId":185938},{"documentUuid":"4da64a3d-0df9-42c0-943d-b05a56f5b942","productRoleGroupId":185936},{"documentUuid":"e485dbee-077f-4f91-89ee-d997ed8307be","productRoleGroupId":185937},{"documentUuid":"7552fb41-dd58-40aa-a4af-8b40b4e435b1","productRoleGroupId":185935},{"documentUuid":"0386b1ea-19fd-424f-94b2-048d6bd91dc5","productRoleGroupId":185934}]},{"id":64088,"type":"SUBSTANTIAL MODIFICATION","status":"Authorised","ctNumber":"2024-518143-38-00","trialStatus":"Authorised","submissionDate":"2025-09-17","partI":{"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-15"},"partIIInfo":[{"id":244885,"mscId":40409,"mscInfo":{"id":40409,"mscName":"France","countryOrganisationId":2012,"assessmentOutcome":"acceptable","assessmentOutcomeDate":"2025-10-09","decision":"authorized","decisionDate":"2024-10-25","reportingStatusCode":"Authorised","countryName":"France","trialStatus":"Authorised","firstDecisionDate":"2024-10-25"},"applicationStatusCode":"Authorised"}],"decisionDate":"2025-10-15","ctMSCsByApplication":[{"id":40409,"mscName":"France","reportingStatusCode":"Authorised"}],"businessKey":"SM-1","modScope":"PART_I_AND_PART_II","allPartTwosOutOfScope":false,"applicationTrialDecisionByMsc":{},"decisions":[{"id":93855,"applicationId":64088,"mscId":40409,"mscName":"France","decisionDate":"2025-10-15T14:45:00.893","decision":"authorized","assessmentOutcome":"acceptable","eventType":"decision","part2Id":244885,"part1Id":101938,"applicationType":"SUBSTANTIAL MODIFICATION","isRMS":true}],"productRoleGroupDocument":[{"documentUuid":"22e96967-2438-4793-8d52-fbaf107977cf","productRoleGroupId":317420},{"documentUuid":"4da64a3d-0df9-42c0-943d-b05a56f5b942","productRoleGroupId":317421},{"documentUuid":"e485dbee-077f-4f91-89ee-d997ed8307be","productRoleGroupId":317422},{"documentUuid":"7552fb41-dd58-40aa-a4af-8b40b4e435b1","productRoleGroupId":317423},{"documentUuid":"0386b1ea-19fd-424f-94b2-048d6bd91dc5","productRoleGroupId":317419},{"documentUuid":"68346806-c183-4a9b-8165-d41591b704ee","productRoleGroupId":317419}]}],"trialGlobalEnd":[],"memberStatesConcerned":[{"mscName":"France","mscId":40409,"firstDecisionDate":"2024-10-25T18:25:35.308","lastDecisionDate":"2025-10-15T14:45:00.893","mscPublicStatusCode":3}],"eudraCt":{"isTransitioned":true,"eudraCtCode":"2017-004309-41"}},"events":{"temporaryHaltList":[],"trialEvents":[{"mscId":40409,"mscName":"France","events":[{"notificationType":"START_OF_TRIAL","date":"2024-10-25"}]}],"unexpectedEvents":[],"seriousBreaches":[],"urgentSafetyMeasures":[]},"results":{},"documents":[{"title":"D1_PROTOCOL 2024-518143-38-00  EN","uuid":"2f2e6530-9175-4b18-bfae-9fe9375f7913","documentType":"104","documentTypeLabel":"Protocol (for publication)","fileType":"PDF","associatedEntityId":101938,"manualVersion":"2.1","systemVersion":"3"},{"title":"D1 SYNOPSIS Porotocol FUNGEMAX  v2 0  27072022","uuid":"60822b76-e22a-4696-9cc5-733f39b25b2b","documentType":"7","documentTypeLabel":"Synopsis of the protocol (for publication)","fileType":"PDF","associatedEntityId":101938,"manualVersion":"2.0","systemVersion":"2"},{"title":"RCP Abraxane 13-05-2022","uuid":"22e96967-2438-4793-8d52-fbaf107977cf","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317420,"manualVersion":"1","systemVersion":"1"},{"title":"RCP ELVORINE MAJ 10022022","uuid":"4da64a3d-0df9-42c0-943d-b05a56f5b942","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317421,"manualVersion":"1","systemVersion":"1"},{"title":"RCP 5FU MAJ 02122021","uuid":"e485dbee-077f-4f91-89ee-d997ed8307be","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317422,"manualVersion":"1","systemVersion":"1"},{"title":"RCP_GEMZAR_25062019","uuid":"7552fb41-dd58-40aa-a4af-8b40b4e435b1","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317423,"manualVersion":"1","systemVersion":"1"},{"title":"RCP ONIVYDE MAJ 08-10-2021","uuid":"0386b1ea-19fd-424f-94b2-048d6bd91dc5","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317419,"manualVersion":"1","systemVersion":"1"},{"title":"E1_RCP ONIVYDE","uuid":"68346806-c183-4a9b-8165-d41591b704ee","documentType":"19","documentTypeLabel":"Summary of Product Characteristics (SmPC) (for publication)","fileType":"PDF","associatedEntityId":317419,"manualVersion":"1.1","systemVersion":"1"},{"title":"document additionnel 04092024","uuid":"ab89d006-9274-4325-ae68-4020a8b170a4","documentType":"14","documentTypeLabel":"Recruitment arrangements (for publication)","fileType":"PDF","associatedEntityId":244885,"manualVersion":"1","systemVersion":"1"},{"title":"L1 SIS and ICF clinical and biological FUNGEMAX V2 0 27072022","uuid":"39b4d38e-95f9-45ea-bc3a-75bb43aa8c7f","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":244885,"manualVersion":"2.0","systemVersion":"2"},{"title":"L1 SIS and ICF addendum FUNGEMAX v1 3 19092019","uuid":"11f609bc-dbe2-46f5-9696-23bbd4dfbb22","documentType":"15","documentTypeLabel":"Subject information and informed consent form (for publication)","fileType":"PDF","associatedEntityId":244885,"manualVersion":"2.0","systemVersion":"2"}],"trialRegion":"EEA","trialRegionCode":1,"correctiveMeasures":[]}